DUBLIN, April 14, 2015 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/rtp6vz/global_cancer) has announced the addition of the "Global Cancer Generics Market Outlook 2018" report to their offering.
The market for cancer generics is expected to grow at 12%, reaching US$ 21 Billion by 2018. Patent expiry, low cost, and better life expectancy would be the major boosting factors for the cancer generics industry.
According to this latest research report Global Cancer Generics Market Outlook 2018, the global oncology market touched a mark of US$ 91 Billion in 2013 and is poised to grow at a CAGR of approximately 6% over the next 5 year period.
With the advent of novel and innovative technologies, industries like healthcare and pharmaceutical are scaling newer heights. One such market is the oncology market. With global cancer incidences rising to almost 14.1 Million in 2012 and several blockbuster cancer drugs losing their patent protection, the market for cancer generics is bound to experience skyrocketing growth.
The report essentially elicits the cancer industry under 2 heads viz. global oncology market and global caner generics market. Hereunder, cancer incidences are discussed providing an insight about the geographical share and country wise incidence rate. Furthermore, the generic cancer drugs are scrutinized according to their dosage form. In addition to that, the cancer generics industry with respect to major indications is also discussed in depth, with emphasis on current and future incidences, regional analysis and patent expiration status of key cancer drugs. Analysis of key industry trends and drivers crucial to the market is also added.
Apart from the above mentioned study parameters the dossier also contains an analysis of the top notch global cancer generics manufacturers. On a holistic basis, the report is primarily inclined towards an in-depth study of the global cancer generics market, asserting the fact that Cancer Generics is going to be the focus area for several industry players, thereby labelling Cancer Generics as a field with substantial growth potential over the next few years.
Key Topics Covered:
1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. Global Cancer Generics Market Analysis 2018
5. Cancer Generic Drugs Industry
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. Cancer Generics Market: Major Indications
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. Market Dynamics
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. Key Players
8.1 Fresenius Kabi AG
8.2 Actavis Plc.
8.4 Teva Pharmaceutical Industries Ltd.
8.6 Sun Pharmaceuticals
For more information visit http://www.researchandmarkets.com/research/rtp6vz/global_cancer
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
SOURCE Research and Markets